Small signaling proteins (8-40 kDa) secreted primarily by leukocytes (macrophages, monocytes, dendritic cells, T cells) that initiate, amplify, and coordinate inflammatory responses across immune, neural, and metabolic systems. Principal members include TNF-α, IL-1β, Interleukin-6, IL-8, IL-12, IL-17, IL-23, and Interferon-gamma, each binding specific cell surface receptors to activate intracellular signaling cascades (NF-κB, JAK-STAT pathway, MAPK) that alter gene transcription, cellular metabolism, and tissue function. These Cytokines operate through autocrine (self-stimulation), paracrine (local neighbor communication), and endocrine (systemic circulation) mechanisms to create coordinated multi-system responses.
Think of inflammatory cytokines as emergency broadcast signals during a neighborhood crisis. When a house catches fire (tissue damage or infection), the first responder macrophages don't just fight the fire themselves—they immediately send out different colored flares into the sky (TNF-α, IL-1β, IL-6). Each colored flare has a specific meaning: the red flare (TNF-α) tells nearby houses to lock their doors and put up barriers (endothelial activation, tight junction changes). The yellow flare (IL-1β) triggers the town's fever alarm at city hall (hypothalamus), raising the ambient temperature to make conditions hostile for invaders. The orange flare (IL-6) travels all the way to the regional factory district (liver) to start mass-producing emergency supplies (acute phase proteins like CRP). Here's the critical part: these flares don't just stay local—some drift on the wind all the way to the mayor's office in the brain, arriving via multiple routes: carried by vagus nerve runners (within 30 minutes), sneaking through checkpoint gaps (circumventricular organs), or even being manufactured locally by brain security guards (microglia). Once the mayor's office receives these distress signals, city-wide policies change: reduced public activities (sickness behavior), altered traffic patterns (metabolism shifts), heightened security patrols (threat sensitivity), and resource reallocation (anorexia, muscle catabolism). The same flares that save the neighborhood can become toxic if they never stop firing—chronic broadcasting eventually exhausts the entire city.
Inflammatory cytokines trigger cellular responses through specific receptor-mediated signaling cascades with distinct intracellular pathways:
TNF-α Signaling:
TNF-α (17 kDa homotrimer) → TNFR1 (ubiquitous) or TNFR2 (immune cells) → receptor trimerization → intracellular death domain (TNFR1) or TRAF2 recruitment (TNFR2) → IKK complex activation → phosphorylation of IκB → IκB degradation → NF-κB (p65/p50 heterodimer) nuclear translocation → transcription of inflammatory genes (IL-6, IL-8, COX-2, iNOS, adhesion molecules VCAM-1/ICAM-1). Parallel pathway: TNF-α → TNFR1 → TRADD → FADD → caspase-8 activation → apoptosis (context-dependent). Additionally: TNF-α → p38 MAPK and ERK activation → AP-1 transcription factor → inflammatory gene expression.
IL-1β Signaling:
IL-1β (17 kDa, cleaved from pro-IL-1β by caspase-1 in NLRP3 inflammasome) → IL-1R1 → recruitment of MyD88 adapter protein → IRAK1/4 activation → TRAF6 → TAK1 → NF-κB and MAPK pathway activation → inflammatory gene transcription. IL-1β reaches hypothalamic OVLT (circumventricular organ lacking blood-brain barrier) → binds IL-1R1 on endothelial cells and neurons → COX-2 induction → Prostaglandin E2 (PGE2) synthesis → PGE2 diffuses to preoptic area → activates EP3 receptors → raises thermoregulatory set-point → fever (increase of 1-4°C).
IL-6 Signaling:
Interleukin-6 (21-28 kDa glycoprotein) → membrane-bound IL-6R (classical signaling) OR soluble IL-6R (trans-signaling) + gp130 co-receptor → receptor heterodimerization → JAK1/JAK2 tyrosine kinases activation → phosphorylation of STAT3 → STAT3 dimerization and nuclear translocation → transcription of target genes. In Liver: IL-6 → hepatocyte STAT3 activation → acute phase proteins (CRP, serum amyloid A, fibrinogen, hepcidin). In brain: IL-6 → hypothalamic STAT3 → altered glucose sensing and appetite regulation. IL-6 also activates MAPK (ERK1/2) and PI3K-AKT pathways.
Brain Access Routes:
- Circumventricular organs (OVLT, area postrema, median eminence): fenestrated capillaries allow direct cytokine entry → local prostaglandin production → signal diffusion to adjacent brain regions
- Vagus nerve: peripheral IL-1β binds receptors on vagal paraganglia → afferent signaling to nucleus tractus solitarius → norepinephrine release in hypothalamus/amygdala (completes within 30 minutes)
- Active transport: saturable carrier-mediated transport across blood-brain barrier (IL-1, IL-6, TNF-α have specific transporters, half-saturation ~10-100 ng/mL)
- Local production: peripheral cytokines → BBB endothelial activation → perivascular macrophages and microglia activation → endogenous CNS cytokine synthesis
Downstream CNS Effects:
Cytokines in brain → activation of insular cortex, anterior cingulate cortex, amygdala → sickness behaviour constellation (lethargy, anorexia, social withdrawal, hyperalgesia, cognitive slowing). Mechanism: IL-1β and TNF-α → induce IDO (indoleamine 2,3-dioxygenase) in microglia → shunts Tryptophan from serotonin synthesis to kynurenine pathway → produces neurotoxic metabolites (quinolinic acid, 3-Hydroxykynurenine) → NMDA receptor activation and oxidative stress → neuroinflammation and Depression.
graph TD
A[Tissue Damage/Infection] --> B[Macrophage Activation]
B --> C["TNF-α Release"]
B --> D["IL-1β Release"]
B --> E[IL-6 Release]
C --> F[TNFR1/2 Binding]
F --> G[IKK Activation]
G --> H["NF-κB Nuclear Entry"]
D --> I[IL-1R1 Binding]
I --> J["MyD88 → IRAK → TRAF6"]
J --> H
E --> K["IL-6R + gp130"]
K --> L[JAK1/2 Activation]
L --> M[STAT3 Phosphorylation]
H --> N[Inflammatory Gene Transcription]
N --> O[More Cytokines]
N --> P[COX-2, iNOS]
N --> Q[Adhesion Molecules]
M --> R[Acute Phase Proteins in Liver]
C --> S[Brain Entry - Multiple Routes]
D --> S
E --> S
S --> T[Vagus Nerve Afferents]
S --> U[Circumventricular Organs]
S --> V[Active BBB Transport]
S --> W[Microglial Activation]
W --> X[IDO Activation]
X --> Y[Kynurenine Pathway]
Y --> Z[Quinolinic Acid]
Z --> AA[NMDA Activation]
AA --> AB[Depression/Cognitive Dysfunction]
D --> AC[Hypothalamic OVLT]
AC --> AD[PGE2 Production]
AD --> AE[Fever Response]
Treatment-Resistant Depression Identification:
Measuring inflammatory cytokines distinguishes inflammatory depression subtypes from classical serotonergic depression. Interleukin-6 >5 pg/mL predicts non-response to SSRIs in ~65% of patients (STAR*D trial subset analyses), while these same patients show 50-60% response rates to infliximab (anti-TNF-α biologic) in clinical trials. This represents application of Metamodel 5 (differential diagnostics) - identifying which selfish system dominates pathology. The selfish immune system hypothesis predicts that when immune activation drives mood symptoms, immune-targeted interventions outperform neurotransmitter-targeted drugs.
Chronic Pain Syndromes:
Elevated TNF-α (>8 pg/mL) and IL-1β (>3 pg/mL) predict transition from acute to chronic pain in musculoskeletal injuries. Inflammatory cytokines sensitize peripheral nociceptors (TRPV1 channels) and drive central sensitisation through microglial activation in spinal dorsal horn. cPNI interventions target cytokine reduction through: omega-3 fatty acids (EPA 2-4g/day reduces IL-6 by 20-30%), intermittent fasting (reduces systemic IL-6 and TNF-α by 15-25%), and movement (acute exercise transiently increases IL-6 from muscle, followed by anti-inflammatory IL-10 rebound).
Evolutionary Mismatch Context:
The sickness behaviour response (mediated by inflammatory cytokines acting on brain) evolved for acute infections lasting days to weeks. In hunter-gatherer contexts, social withdrawal, anorexia, and lethargy were adaptive—conserving energy and reducing pathogen transmission. Modern chronic inflammation from metabolic-syndrome, gut dysbiosis, or chronic stress creates persistent cytokine elevation, producing maladaptive chronic sickness behavior misdiagnosed as primary psychiatric disease. The system designed for short-term defense becomes long-term pathology.
Metamodel 0 Application:
Inflammatory cytokines create multi-system dysregulation fitting the "one illness paradigm." A patient with elevated IL-6 doesn't have separate diagnoses of depression, insulin resistance, fatigue, and pain—they have cytokine-mediated system dysfunction manifesting across domains. Treatment addresses root causes (gut barrier dysfunction, chronic stress, metabolic dysregulation) rather than symptom suppression in individual systems.
Clinical Decision Points:
- IL-6 >10 pg/mL: consider gut barrier assessment, screen for SIBO/dysbiosis, evaluate chronic infections
- CRP >3 mg/L with normal IL-6: suggests primarily hepatic acute phase response, investigate metabolic drivers
- TNF-α >12 pg/mL: high probability of treatment-resistant depression if psychiatric symptoms present; consider anti-inflammatory interventions before escalating psychotropic medications
- Normal cytokine panel with severe symptoms: suggests non-inflammatory mechanism; investigate HPA axis dysfunction, mitochondrial issues, or psychological trauma as primary drivers
Intervention Hierarchy (Metamodel 2 - Evolutionary Expectations):
- Address evolutionary mismatches: restore circadian rhythm, increase movement, optimize sleep, reduce processed food exposure
- Gut barrier restoration: eliminate trigger foods, repair with L-glutamine/zinc carnosine, restore microbiome diversity
- Anti-inflammatory nutrition: increase omega-3 index to >8%, emphasize polyphenols, reduce omega-6:omega-3 ratio to <4:1
- Stress axis regulation: vagus nerve stimulation exercises, cold exposure, breathwork to reduce sympathetic tone
- Targeted supplementation: curcumin (1g/day with piperine), resveratrol (500mg/day), vitamin D optimization (>40 ng/mL)
- Pharmacological consideration: only if above approaches fail and cytokine levels remain >2x reference range
- IL-6 half-life: ~6 hours in circulation; peak levels 2-4 hours post-stimulus, return to baseline by 24-48 hours in acute inflammation
- Brain penetration timing: TNF-α reaches brain parenchyma within 30 minutes of peripheral injection via vagal afferents; peak brain concentration at 2-3 hours via active transport
- Depression prediction threshold: IL-6 >5 pg/mL predicts 65% non-response to SSRIs; CRP >3 mg/L increases odds ratio for treatment-resistant depression to 2.4
- IFN-α therapy: causes major depressive episode in 30-50% of hepatitis C patients receiving treatment; risk increases with IL-6 baseline >2 pg/mL
- Fever mechanism: IL-1β at OVLT induces COX-2 → PGE2 production → EP3 receptor activation raises hypothalamic set-point by 2-4°C within 90-120 minutes
- Anti-TNF response rate: ~50% of patients with inflammatory depression (CRP >3 mg/mL + depression) respond to infliximab 5mg/kg; response correlates with baseline TNF-α >8 pg/mL
- Kynurenine shunt: inflammatory cytokines increase IDO activity 5-10 fold → 60-70% of tryptophan diverted from serotonin to kynurenine pathway within 6-12 hours
- Muscle catabolism: TNF-α and IL-1β activate ubiquitin-proteasome system → 3-5% muscle protein breakdown per day during acute inflammation; chronic elevation drives sarcopenia
- Exercise paradox: acute bout increases IL-6 by 100-fold from muscle (myokine function), but chronic training reduces baseline IL-6 by 30-40% (anti-inflammatory adaptation)
- Circadian variation: IL-6 and TNF-α peak at 04:00-06:00, nadir at 16:00-20:00; disrupted in chronic inflammation and depression (flattened rhythm or phase-shifted)
- Vagal sensitivity: IL-1β activates vagal afferents at concentrations of 0.1-1 ng/mL (below systemic detection threshold); provides early warning system before measurable blood levels
- BBB transport saturation: IL-1 transporter saturates at ~50 ng/mL plasma concentration; above this, additional peripheral cytokine doesn't proportionally increase brain levels
- TNF-α — prototypical inflammatory cytokine that activates NF-κB and drives acute phase response, central to rheumatoid arthritis and inflammatory depression pathophysiology
- IL-1β — pyrogenic cytokine processed by NLRP3 inflammasome, induces fever via hypothalamic PGE2 production and drives peripheral pain sensitization
- Interleukin-6 — pleiotropic cytokine with both pro-inflammatory (acute) and anti-inflammatory (chronic exercise) context-dependent effects, signals via JAK-STAT3
- IL-8 — CXC chemokine recruiting neutrophils to infection/injury sites, elevated in acute bacterial infections and tissue damage
- Interferon-gamma — Th1 signature cytokine activating macrophages, induces IDO and MHC-II expression, drives cell-mediated immunity against intracellular pathogens
- IL-17 — Th17 cytokine driving autoimmune inflammation in psoriasis, ankylosing spondylitis, and inflammatory bowel disease through neutrophil recruitment
- NF-κB — master transcription factor activated by TNF-α and IL-1β, drives expression of >400 inflammatory genes including cytokines, chemokines, and adhesion molecules
- JAK-STAT pathway — primary signaling cascade for IL-6, IL-10, and interferons; STAT3 activation induces acute phase proteins and modulates metabolic function
- insular cortex — primary brain region integrating peripheral inflammatory signals into conscious symptom perception (fatigue, malaise, pain sensitivity)
- Depression — inflammatory subtype mediated by cytokine-induced IDO activation, kynurenine pathway dysregulation, and reduced hippocampal neurogenesis
- sickness behaviour — adaptive behavioral response to infection (lethargy, anorexia, social withdrawal) mediated by cytokine action on hypothalamus and limbic system
- fever — thermoregulatory response triggered by IL-1β and IL-6 acting on hypothalamic circumventricular organs to produce PGE2
- Vagus nerve — rapid neural pathway conveying peripheral inflammatory signals to brainstem nucleus tractus solitarius within minutes, bypassing blood-brain barrier
- Circumventricular organs — specialized brain regions (OVLT, area postrema) with fenestrated capillaries allowing direct cytokine access to CNS tissue
- blood-brain barrier — actively transports inflammatory cytokines via saturable carrier systems; transport capacity overwhelmed in severe inflammation leading to direct penetration
- IDO — indoleamine 2,3-dioxygenase enzyme activated by IFN-γ and TNF-α, shunts tryptophan from serotonin to neurotoxic kynurenine metabolites
- kynurenine pathway — tryptophan degradation route producing quinolinic acid (NMDA agonist) and 3-hydroxykynurenine (oxidative toxin) implicated in depression and neurodegeneration
- acute phase proteins — hepatic proteins (CRP, SAA, hepcidin, fibrinogen) induced by IL-6 via STAT3, serve as clinical biomarkers of systemic inflammation
- chronic inflammation — persistent elevation of inflammatory cytokines driving metabolic syndrome, cardiovascular disease, neurodegeneration, and treatment-resistant psychiatric illness
- NLRP3 inflammasome — intracellular multi-protein complex activated by DAMPs and PAMPs, processes pro-IL-1β to active IL-1β via caspase-1 cleavage
- microglia — resident CNS immune cells that produce inflammatory cytokines in response to peripheral signals, driving neuroinflammation and altered neurotransmission
- gut dysbiosis — altered microbiome composition increases LPS translocation, activating TLR4 → inflammatory cytokine production → systemic low-grade inflammation
- insulin resistance — TNF-α and IL-6 impair insulin receptor signaling through serine phosphorylation of IRS-1, creating metabolic-immune crosstalk in obesity
- HPA axis — bidirectional regulation with inflammatory cytokines: cytokines activate CRH release, while cortisol normally suppresses cytokine production (feedback disrupted in chronic stress)
- Cortisol resistance — chronic inflammatory cytokine exposure downregulates glucocorticoid receptors, reducing cortisol's anti-inflammatory effects and perpetuating inflammation
- acute phase response — coordinated liver response to IL-6 producing positive acute phase reactants (CRP, ferritin, fibrinogen) and reducing negative reactants (albumin, transferrin)
- COX-2 — inducible cyclooxygenase enzyme upregulated by NF-κB, converts arachidonic acid to prostaglandins including PGE2 critical for fever and pain sensitization
- Specialized pro-resolving mediators (SPMs) — lipid mediators (resolvins, protectins, maresins) that actively terminate inflammatory cytokine signaling and promote resolution